Promomed Company will expand the production of pharmaceutical substances for the production of innovative medicines

The Saransk Biochemist plant is planning to launch the country's largest production of domestic pharmaceutical substances. In the future, Russia will be able to export its own innovative medicines with no less success than oil, gas and nuclear energy.

This statement was made at the St. Petersburg International Economic Forum (SPIEF) by Peter Bely, Chairman of the Board of Directors of Promomed Group of Companies. In an interview with RG, the interlocutor spoke about import substitution and the prospects for the development of the domestic pharmaceutical industry in modern conditions.

Peter Alexandrovich, in April, at an off-site meeting of the Council on Intellectual Property of the Federation Council in Saransk, you stated that, despite the sanctions, there would be no shortage of medicines in the country: Russian manufacturers are ready to provide the domestic market with the necessary drugs. What is the basis for such optimism? In which groups of medicines is the situation the most favorable today, and in which areas, in your opinion, should our pharmaceutical companies strengthen their work?

Peter Bely: For all key nosologies, Russia currently produces enough medicines to fully meet the needs of healthcare without interruptions. Moreover, many substances for ready—made dosage forms are being made in the Russian Federation, and this process is on the rise. I am pleased to say that Promomed is opening one of the country's largest production facilities for active pharmaceutical substances at its Biochemist plant in the coming months. These are seven workshops, three of which are dedicated to the synthesis of oncological molecules, with a total of more than 150 names of active molecules. The new site will be a huge step forward. And the entire domestic pharmaceutical industry is now doing a lot to ensure that the issue of drug sufficiency is not on our agenda at all.

Today, it is very important for the Russian pharmaceutical industry to transform the practice of the generic development model into an innovative one. As correctly formulated in the Pharma 2030 concept, our goal is to have our own original drugs in all key therapeutic groups, and to ensure that these molecules are properly protected by patents. Because the appearance of a large number of innovative drugs is a qualitatively new level of healthcare. And for the country's economy, it is a new resource for export potential. After all, new medicines are something that Russia can export with no less success than oil, gas, nuclear energy, etc. This is the next challenge that we have to face. We have learned how to produce any generic drugs — now we need to learn how to produce innovative medicines in sufficient quantities in the most important therapeutic groups.

And a separate big challenge facing the industry is the need to create an entire system for the production of biotechnological medicines. This is a new generation of therapy. There are more and more such drugs appearing in the world — for those diseases that have not been treated before, or those that can be treated more effectively and safely. Our company is also taking important steps in this direction.

At the same meeting on intellectual property issues, you mentioned the regulatory disparity between domestic drug manufacturers and Western companies as one of the main problems of the pharmaceutical industry. In particular, it was mentioned that today it is necessary to create a system that would stimulate and support the withdrawal of Russian innovative medicines. What steps do you expect the government to take to achieve this?

Peter the White: This is the most important topic. From the Soviet past, we inherited a kind of "prohibitive" system for reviewing patent applications, in which many aspects of the breadth of legal protection are cut off at the review stage. At the same time, we see other practices in the world where applicants, on the contrary, receive the maximum amount of legal protection for their intellectual property.

And we must admit that positive changes are already taking place. Today, Rospatent is facing the industry. Mechanisms for such accelerated consultation have already been created, when not only pharmaceutical companies, but also research teams from universities or research centers can contact Rospatent directly, get advice on how patentable an invention is, how evidence needs to be strengthened, and where it is better to direct efforts to obtain the maximum amount of blocking protection. It is absolutely, critically necessary that our industry uses the same practice of patent protection formation as the world's leading pharmaceutical companies. And then our developments will receive a system platform for development in foreign markets.

Source: rg.ru

315" src="https://www.youtube.com/embed/9hEnYOhYZgk " title="Rossiyskaya gazeta: Promomed to expand production of pharmaceutical substances" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen>

1. https://rg.ru/2022/06/18/kompaniia-promomed-rasshirit-vypusk-farmsubstancij-dlia-proizvodstva-innovacionnyh-lekarstv.html